-
公开(公告)号：US12043654B2
公开(公告)日：2024-07-23
申请号：US17331289
申请日：2021-05-26
发明人： Lei Xiao , Xiaogang Shen , Wensheng Wang , Dongqi Chen , Beibei Jia , Chengfei Pu , Le Tian
IPC分类号： C07K16/40 , A61K35/17 , A61P35/00 , C07K14/725 , A61K38/00
CPC分类号： C07K14/7051 , A61K35/17 , A61P35/00 , C07K16/40 , A61K38/00 , C12Y406/01002
摘要： The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).
-
公开(公告)号：US11970548B2
公开(公告)日：2024-04-30
申请号：US17821706
申请日：2022-08-23
发明人： Zhiyuan Cao , Yuzhe Peng , Lei Xiao , Zhao Wu , Le Tian
IPC分类号： C12P21/08 , A61K35/17 , A61K39/395 , A61K47/68 , A61P35/00 , C07K14/725 , C07K16/28 , C07K16/30 , C07K16/40 , A61K38/00
CPC分类号： C07K16/40 , A61K35/17 , A61P35/00 , C07K14/7051 , A61K38/00 , C07K2317/56 , C12Y406/01002
摘要： The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.
-
公开(公告)号：US11944645B2
公开(公告)日：2024-04-02
申请号：US17490582
申请日：2021-09-30
发明人： Zhiyuan Cao , Lei Xiao , Yuzhe Peng , Wei Ding , Wensheng Wang
IPC分类号： A61K35/17 , C07K14/47 , C07K14/725
CPC分类号： A61K35/17 , C07K14/4702 , C07K14/7051
摘要： The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.
-
公开(公告)号：US20230227779A1
公开(公告)日：2023-07-20
申请号：US18156482
申请日：2023-01-19
发明人： Xiaogang Shen , Xudong Tang , Chengfei Pu , Lei Xiao , Le Tian
CPC分类号： C12N5/0636 , C07K14/5412 , C07K14/57 , C07K14/5443 , C07K14/5434 , C07K16/28 , C07K16/303 , C07K16/40 , C12N2500/02 , C07K2319/03 , C07K2319/33 , C07K2319/02 , C12N2510/00 , A61K2039/505
摘要： Embodiments of the present disclosure relate to compositions and methods of enhancing lymphocytes' ability to treat cancer patients. Embodiments relate to a polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR), a nucleic acid encoding an Oxygen-Dependent Degradation domain (ODD), and a nucleic acid encoding one or multiple sequences of Hypoxia-Response Element (HRE).
-
公开(公告)号：US20230201258A1
公开(公告)日：2023-06-29
申请号：US17996589
申请日：2021-04-21
发明人： Chengfei Pu , Lei Xiao , Jingrui Liu , Junkai Peng , Le Tian , Xiaogang Shen , Zhiyuan Cao , Zhao Wu
IPC分类号： A61K35/17 , A61P35/00 , A61K39/395
CPC分类号： A61K35/17 , A61P35/00 , A61K39/39541 , A61K2039/505
摘要： The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTE®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.
-
公开(公告)号：US20220348682A1
公开(公告)日：2022-11-03
申请号：US17270571
申请日：2019-08-29
发明人： Lei Xiao , He Sun , Zhiyuan Cao , Wensheng Wang , Chengfei Pu , Li Mao
IPC分类号： C07K16/30 , C07K14/725 , A61K47/68
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
-
公开(公告)号：US20220249557A1
公开(公告)日：2022-08-11
申请号：US17592601
申请日：2022-02-04
发明人： Yang Li , Zhiyuan Cao , Wei Ding , Xianyang Jiang , Chengfei Pu , Le Tian , Christopher Ballas , Zhao Wu , Lei Xiao
IPC分类号： A61K35/17 , C07K14/725 , A61K47/69
摘要： The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.
-
公开(公告)号：US20210252059A1
公开(公告)日：2021-08-19
申请号：US17173504
申请日：2021-02-11
发明人： Chengfei Pu , Zhiyuan Cao , Zhao Wu , Lei Xiao
IPC分类号： A61K35/17 , C07K14/54 , C07K14/55 , C07K14/535
摘要： The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1α, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFNγ.
-
公开(公告)号：US20210230308A1
公开(公告)日：2021-07-29
申请号：US17220387
申请日：2021-04-01
发明人： Lei Xiao , He Sun , Zhiyuan Cao , Wensheng Wang , Chengfei Pu , Li Mao
摘要： The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
-
公开(公告)号：US20210137983A1
公开(公告)日：2021-05-13
申请号：US17091741
申请日：2020-11-06
发明人： Lei Xiao , Chengfei Pu , Zhiyuan Cao , Le Tian
IPC分类号： A61K35/17 , C07K14/54 , C07K14/57 , C07K14/705 , A61P35/00
摘要： The present disclosure relates to compositions and methods for enhancing NK cell response and/or maintenance in vivo and/or in vitro. For example, a method of enhancing NK cell-based therapy comprises administering a mixed population of NK cells comprising modified NK cells comprising a first chimeric antigen receptor (CAR) and modified NK cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.034 秒)
